1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,070 | 1,110 | 21.01. | |
| 1,050 | 1,120 | 21.01. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.01. | NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025 | 338 | ACCESS Newswire | SHELTON, CT / ACCESSWIRE / January 13, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus... ► Artikel lesen | |
| NANOVIRICIDES Aktie jetzt für 0€ handeln | |||||
| 08.01. | NanoViricides: Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals | 467 | ACCESS Newswire | SHELTON, CT / ACCESSWIRE / January 8, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), comments on the many viruses that could cause pandemics that are... ► Artikel lesen | |
| 23.12.24 | NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape | 1.655 | ACCESS Newswire | SHELTON, CT / ACCESSWIRE / December 23, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), says that its broad-spectrum antiviral drug candidate NV-387 is the best weapon to fight a potential... ► Artikel lesen | |
| 12.12.24 | NANOVIRICIDES, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 15.11.24 | NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID | 473 | ACCESS Newswire | SHELTON, CT / ACCESSWIRE / November 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the quarter ending September... ► Artikel lesen | |
| 04.11.24 | NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am | 656 | ACCESS Newswire | SHELTON, CT / ACCESSWIRE / November 4, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that... ► Artikel lesen | |
| 22.10.24 | NanoViricides President Dr. Diwan to Present at the PODD Conference | 334 | ACCESS Newswire | SHELTON, CT / ACCESSWIRE / October 22, 2024 / NanoViricides, Inc. (NYSE Amer.: NNVC ) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that... ► Artikel lesen | |
| 15.10.24 | NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology | 501 | ACCESS Newswire | SHELTON, CT / ACCESSWIRE / October 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that... ► Artikel lesen | |
| 14.10.24 | NanoViricides Inc. (NNVC): Best Nanotech Penny Stock to Buy | 2 | Insider Monkey | ||
| 08.10.24 | InvestorNewsBreaks - NanoViricides Inc. (NYSE American: NNVC) to Discuss Its 'Trojan Horse' Platform Technology at Upcoming Global AMR Summit | 1 | iNVEZZ.com | ||
| 08.10.24 | NanoViricides to Present at the Global AMR Summit 2024 Tomorrow | 474 | ACCESS Newswire | Dr. Diwan to Discuss "Shape-Shifting", "Trojan Horse", Pathogen-Directed Attack Capability of NanoViricides Platform Technology to Combat AMR SHELTON, CT / ACCESSWIRE / October 8, 2024 / NanoViricides... ► Artikel lesen | |
| 30.09.24 | NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID | 481 | ACCESS Newswire | SHELTON, CT / ACCESSWIRE / September 30, 2024 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30... ► Artikel lesen | |
| 27.09.24 | NANOVIRICIDES, INC. - 10-K, Annual Report | 3 | SEC Filings | ||
| 26.09.24 | NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including "Trojan Horse" Drugs | 640 | ACCESS Newswire | SHELTON, CT / ACCESSWIRE / September 26, 2024 / NanoViricides, Inc. (NYSE American.:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports today that... ► Artikel lesen | |
| 26.08.24 | MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX | 613 | ACCESS Newswire | SHELTON, CT / ACCESSWIRE / August 26, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports today that it... ► Artikel lesen | |
| 19.08.24 | NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 -A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections | 939 | ACCESS Newswire | SHELTON, CT / ACCESSWIRE / August 19, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, is providing an update... ► Artikel lesen | |
| 09.08.24 | NanoViricides extends executive contracts, grants stock | 1 | Investing.com | ||
| 09.08.24 | NANOVIRICIDES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.08.24 | NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics | 593 | ACCESS Newswire | SHELTON, CT / ACCESSWIRE / August 8, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, is providing an update... ► Artikel lesen | |
| 01.08.24 | "NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides | 755 | ACCESS Newswire | SHELTON, CT / ACCESSWIRE / August 1, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports that two separate... ► Artikel lesen |
Seite:
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 54,30 | -3,72 % | Formycon: Zulassung für Bayer-Konkurrent schiebt an | Gute Nachrichten schieben heute Vormittag Formycon an: Der Entwickerl von so genannten Biosimiliars hat für ein Augenmedikament eine EU-weite Zulassung erhalten. Der Wirkstoff FYB203 soll dem Erfolgsprodukt... ► Artikel lesen | |
| KOPIN | 1,210 | -1,94 % | Kopin Secures $2 Mln Follow-On Order For Brillian AMLCD Microdisplays In Rotary, Fixed Pilot Helmet | WASHINGTON (dpa-AFX) - Kopin Corp. (KOPN), a company in the development of high-performance microdisplays and optical systems, Tuesday announced a $2 million follow-on production order for its... ► Artikel lesen | |
| ONTO INNOVATION | 212,00 | 0,00 % | Onto Innovation CEO verkauft Aktien im Wert von 6,34 Millionen US-Dollar | ||
| VEECO INSTRUMENTS | 26,400 | +0,76 % | Veeco Instruments Inc.: Veeco Updates Fourth Quarter and Full Year 2024 Guidance | PLAINVIEW, N.Y., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Veeco Instruments Inc. (NASDAQ: VECO) today has updated its financial guidance for the fourth quarter and full year 2024. We expect revenue for... ► Artikel lesen | |
| NVE | 80,00 | +0,63 % | NVE Q3 Earnings Preview | ||
| GAUZY | 11,500 | +6,78 % | GAUZY LTD: Gauzy's and Journeo's Strategic Partnership on Track to Enhance Road Safety on London's Fleet of 8,500 Buses With Smart-Vision Advanced Driver Assistance System (ADAS) | ||
| ZENTEK | 1,090 | +1,87 % | Zentek Provides Update on ZenGUARD Enhanced Air Filters for the Canadian Market | GUELPH, ON / ACCESS Newswire / January 17, 2025 / Zentek Ltd. ("Zentek" or the "Company") (NASDAQ:ZTEK)(TSXV:ZEN), an intellectual property development and commercialization company, is pleased to provide... ► Artikel lesen | |
| FENDX TECHNOLOGIES | 0,100 | +1,42 % | FendX Technologies Inc.: FendX Announces RSU Grant | Oakville, Ontario--(Newsfile Corp. - December 19, 2024) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the "Company" or "FendX"), a nanotechnology company developing surface protection... ► Artikel lesen | |
| DOTZ NANO | 0,053 | +5,00 % | DOTZ NANO LIMITED: Dotz 2025 Corporate Deck | ||
| ACACIA RESEARCH | 4,140 | -0,48 % | Acacia Research Reports Third Quarter 2024 Financial Results | NEW YORK--(BUSINESS WIRE)--Acacia Research Corporation (Nasdaq: ACTG) ("Acacia" or the "Company"), which acquires and operates businesses across the industrial, energy and technology sectors, today... ► Artikel lesen | |
| ADVANCE ZINCTEK | 0,456 | -0,44 % | ADVANCE ZINCTEK LIMITED: Change of Director's Interest Notice - Lev Mizikovsky | ||
| LEHNER INVESTMENTS | 0,022 | 0,00 % | EQS-News: LEHNER INVESTMENTS AG: Alpay Ece verstärkt den Vorstand | EQS-News: LEHNER INVESTMENTS AG
/ Schlagwort(e): Personalie
LEHNER INVESTMENTS AG: Alpay Ece verstärkt den Vorstand
25.11.2024 / 16:15 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| NANOFOCUS | 1,260 | +0,80 % | NanoFocus passt Prognose für 2024 an | Die NanoFocus AG hat heute beschlossen, die Prognose für das laufende Jahr anzupassen. Aufgrund von gegenwärtig absehbar deutlich niedrigeren Umsätzen in den Bereichen Semiconductor Asia und Standard/Labor... ► Artikel lesen | |
| RIBER | 3,340 | -2,05 % | RIBER secures a repeat order for an MBE 412 cluster system in the USA | RIBER secures a repeat order for an MBE 412 cluster system in the USA Bezons (France), January 9, 2025 - 8:00am (CET) - RIBER, the global leader for Molecular Beam Epitaxy (MBE) equipment serving... ► Artikel lesen | |
| GOMSPACE | 0,316 | 0,00 % | GomSpace Group AB: GomSpace returns to comprehensive market guidance with strong outlook for 2025 | The company is indicating a year-on-year revenue growth of more than 30%, strong EBITDA improvement, and positive free cashflow for full year 2025. The company will deliver positive free cashflow for... ► Artikel lesen |
Das Unternehmen NANOVIRICIDES INC kann der Branche Nanotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,070 Euro und damit -5,31 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOVIRICIDES INC finden Sie auf Wallstreet Online.
